Related Experiment Video
Updated: Jul 4, 2026
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
Efficacy and Safety of Microneedling Combined With Mesotherapy for Androgenic Alopecia: A Retrospective Study
Elham Behrangi1, Roya Zeinali1, Paria Jafari1
1Department of Dermatology, Hazrat Fatemeh Hospital, School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran.
Background And Aims:
Androgenic alopecia (AGA) is a prevalent form of hair loss characterized by progressive miniaturization of hair follicles, significantly impacting patients' self-confidence and quality of life. Current FDA-approved treatments demonstrate limited to moderate efficacy. Microneedling combined with mesotherapy techniques has emerged as a promising drug delivery system for enhancing therapeutic outcomes in hair loss disorders. This retrospective interventional study aimed to evaluate the efficacy and safety of four distinct microneedling-based mesotherapy protocols for the treatment of androgenic alopecia.
Methods:
Sixty-three patients with clinically confirmed AGA were allocated to four treatment groups. All groups received microneedling therapy combined with different mesotherapy formulations: Group I (n = 16) received 2 mL hyaluronic acid (HA); Group II (n = 20) received 1.5 mL HA plus 0.5 mL finasteride; Group III (n = 15) received 1.5 mL HA plus 0.5 mL latanoprost; and Group IV (n = 12) received 1 mL HA plus 0.5 mL finasteride and 0.5 mL latanoprost. Patients underwent six treatment sessions at 3-4 week intervals. Standardized digital photographs were obtained at baseline, 3 months, and 6 months. Efficacy was assessed using physician satisfaction scores (treating and blinded evaluators) and patient satisfaction scores. Safety was monitored after each treatment session.
Results:
Thirty-nine women and 24 men completed the study. Women demonstrated significantly higher improvement rates (48%) compared to men (29%). Female pattern hair loss showed better response (45%) than male pattern AGA (37.5%). Participants under 30 years achieved higher improvement rates (47%) compared to those aged 30-49 years (42.9%). Group IV (combination therapy with finasteride and latanoprost) demonstrated the highest efficacy across both sexes and hair loss patterns. All treatment protocols were well-tolerated with minimal adverse effects.
Conclusions:
The findings of the current study support the use of combination mesotherapy protocols for enhanced therapeutic outcomes in AGA management.
